Syed Umar, MD
Psychiatry · Somerset, KYNPI 1316043540
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 414 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,428, 2.7 times the $527 reported in 2019. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 414 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$965
- AbbVie$935
- Lundbeck LLC$812
- Takeda Pharmaceuticals U.S.A., Inc.$517
- Almatica Pharma LLC$445
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,87899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 73 | $1,129 |
| Alkermes, Inc. | 50 | $965 |
| AbbVie(2 entities) | 63 | $935 |
| Lundbeck LLC | 42 | $812 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $517 |
| Almatica Pharma LLC | 28 | $445 |
| Johnson & Johnson | 21 | $383 |
| Vanda Pharmaceuticals Inc. | 28 | $380 |
| Axsome Therapeutics, Inc. | 13 | $264 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $261 |
| Sunovion Pharmaceuticals Inc. | 9 | $176 |
| Ironshore Pharmaceuticals Inc. | 8 | $152 |
| E.r. Squibb & Sons, L.L.C. | 7 | $126 |
| Teva Pharmaceuticals USA, Inc. | 7 | $125 |
| Idorsia Pharmaceuticals US Inc | 4 | $73 |
| Indivior Inc. | 2 | $43 |
| Eisai Inc. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Neuronetics, Inc. | 2 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$6,963 in reported general payments places this provider in the 90th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 153 | $217,976 |
| Invega SustennaPaliperidone Palmitate | 50 | $135,598 |
| Abilify MaintenaAripiprazole | 27 | $79,005 |
| Lurasidone Hcl | 166 | $41,341 |
| RexultiBrexpiprazole | 22 | $31,265 |
| TrintellixVortioxetine Hydrobromide | 64 | $29,530 |
| Aripiprazole | 391 | $26,353 |
| CaplytaLumateperone Tosylate | 13 | $19,424 |
| Quetiapine Fumarate | 821 | $12,310 |
| SeroquelQuetiapine Fumarate | 12 | $11,183 |
| Paliperidone ErPaliperidone | 33 | $10,478 |
| Divalproex Sodium ErDivalproex Sodium | 185 | $10,243 |
| FetzimaLevomilnacipran Hcl | 12 | $6,502 |
| Olanzapine | 167 | $6,385 |
| Clonazepam | 1,314 | $6,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima, Lexapro | $935 | $229,255176 claims |
| Johnson & JohnsonInvega Sustenna | $383 | $135,59850 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,129 | $110,27149 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $517 | $29,53064 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $261 | $19,42413 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $445 | $7,719506 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Somerset
- Robina BokhariSomerset$8K
- Carmen PintoElizabethtown$1.7M
- Rifaat El-MallakhLouisville$1.6M
- Robert StewartLouisville$651K
- Mark WrightLexington$637K
- Carol MillerFrankfort$462K
- Ali FarooquiLouisville$393K
- Steven CroleyLexington$151K
- Joseph HarrisonOwensboro$131K
- Stephanie HallLouisville$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.